pharma · Non-Muscle Invasive Bladder Urothelial Carcinoma · Nasopharyngeal Cancinoma (NPC)
Chongqing Daxin Pharmaceutical
Chongqing Claruvis Pharmaceutical Co.,
Chongqing Claruvis Pharmaceutical is a pharma organization headquartered in CN. Primary therapeutic focus areas include Non-Muscle Invasive Bladder Urothelial Carcinoma, Nasopharyngeal Cancinoma (NPC). NovaPharmaNews lin
Chongqing, CN HQ
5 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Chongqing, CN
- Employees
- 5
- Programs
- 2
- Drugs
- 6
- Patents
- 0
Irinotecan liposome II combination therapy regimen
Phase 1 · small molecule · Non-Muscle Invasive Bladder Urothelial Carcinoma
Irinotecan liposome II combination therapy regimen for Non-Muscle Invasive Bladder Urothelial Carcinoma is a Phase 1 program (small_molecule) at Chongqing Claruvis Pharmaceutical Co., with 1 ClinicalTrials.gov record(s).
Internal code 2024-549-02
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Chongqing Claruvis Pharmaceutical Co.,
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Status
- active
- Trials
- 1